Trial Outcomes & Findings for The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery (NCT NCT00413244)

NCT ID: NCT00413244

Last Updated: 2017-01-05

Results Overview

Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

51 participants

Primary outcome timeframe

at 6 months

Results posted on

2017-01-05

Participant Flow

Subjects recruited for the study were male patients with stable cardiac status at least 3 months after Percutaneous Coronary Intervention (PCI) at the Cardiac Catheterization Lab of Mount Sinai Hospital from July 2007 to August 2013.

Participant milestones

Participant milestones
Measure
Androgel
Androgel 5 grams
Placebo
Matching Placebo
Overall Study
STARTED
31
20
Overall Study
COMPLETED
21
19
Overall Study
NOT COMPLETED
10
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Androgel
Androgel 5 grams
Placebo
Matching Placebo
Overall Study
Withdrawal by Subject
10
1

Baseline Characteristics

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
Total
n=51 Participants
Total of all reporting groups
Age, Continuous
58.3 years
STANDARD_DEVIATION 8.2 • n=99 Participants
58.9 years
STANDARD_DEVIATION 7.3 • n=107 Participants
58.5 years
STANDARD_DEVIATION 7.81 • n=206 Participants
Gender
Female
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Gender
Male
31 Participants
n=99 Participants
20 Participants
n=107 Participants
51 Participants
n=206 Participants
Hypertension
Yes
30 participants
n=99 Participants
16 participants
n=107 Participants
46 participants
n=206 Participants
Hypertension
No
1 participants
n=99 Participants
4 participants
n=107 Participants
5 participants
n=206 Participants
Body Mass Index
30.8 kg/m^2
STANDARD_DEVIATION 5.8 • n=99 Participants
28.0 kg/m^2
STANDARD_DEVIATION 4.3 • n=107 Participants
29.7 kg/m^2
STANDARD_DEVIATION 5.4 • n=206 Participants
Diabetes
Yes
16 participants
n=99 Participants
6 participants
n=107 Participants
22 participants
n=206 Participants
Diabetes
No
15 participants
n=99 Participants
14 participants
n=107 Participants
29 participants
n=206 Participants
Total Testosterone
246.7 ng/dL
STANDARD_DEVIATION 63.5 • n=99 Participants
263.7 ng/dL
STANDARD_DEVIATION 71.9 • n=107 Participants
253.36 ng/dL
STANDARD_DEVIATION 66.8 • n=206 Participants
Systolic Blood Pressure
123.81 mmHg
STANDARD_DEVIATION 13.81 • n=99 Participants
128.05 mmHg
STANDARD_DEVIATION 20.84 • n=107 Participants
125.47 mmHg
STANDARD_DEVIATION 16.85 • n=206 Participants
Diastolic Blood Pressure
76.32 mmHg
STANDARD_DEVIATION 9.03 • n=99 Participants
75.10 mmHg
STANDARD_DEVIATION 11.65 • n=107 Participants
75.84 mmHg
STANDARD_DEVIATION 10.04 • n=206 Participants
Hematocrit
40.69 percent of cells
STANDARD_DEVIATION 3.00 • n=99 Participants
40.93 percent of cells
STANDARD_DEVIATION 3.18 • n=107 Participants
40.78 percent of cells
STANDARD_DEVIATION 3.04 • n=206 Participants
White Blood Cell Count
6.25 cells x10^3/uL
STANDARD_DEVIATION 1.78 • n=99 Participants
6.49 cells x10^3/uL
STANDARD_DEVIATION 1.63 • n=107 Participants
6.34 cells x10^3/uL
STANDARD_DEVIATION 1.71 • n=206 Participants
Red Blood Cell Count
4.58 cells x10^6/uL
STANDARD_DEVIATION 0.44 • n=99 Participants
4.67 cells x10^6/uL
STANDARD_DEVIATION 0.42 • n=107 Participants
4.62 cells x10^6/uL
STANDARD_DEVIATION 0.43 • n=206 Participants
Aging male syndrome questionnaire
36.48 units on a scale
STANDARD_DEVIATION 11.36 • n=99 Participants
35.85 units on a scale
STANDARD_DEVIATION 10.24 • n=107 Participants
36.24 units on a scale
STANDARD_DEVIATION 10.83 • n=206 Participants
Exercise Time
507.29 seconds
STANDARD_DEVIATION 153.48 • n=99 Participants
530.00 seconds
STANDARD_DEVIATION 120.08 • n=107 Participants
516.20 seconds
STANDARD_DEVIATION 104.49 • n=206 Participants
International Prostate Symptom Score (IPSS)
5.68 units on a scale
STANDARD_DEVIATION 4.77 • n=99 Participants
4.55 units on a scale
STANDARD_DEVIATION 4.7 • n=107 Participants
5.24 units on a scale
STANDARD_DEVIATION 4.73 • n=206 Participants
Metabolic equivalent of task (METs)
10.03 MET units
STANDARD_DEVIATION 2.58 • n=99 Participants
10.05 MET units
STANDARD_DEVIATION 1.99 • n=107 Participants
10.04 MET units
STANDARD_DEVIATION 2.34 • n=206 Participants
Reactive hyperemia index (RHI)
1.97 ml
STANDARD_DEVIATION 0.72 • n=99 Participants
1.85 ml
STANDARD_DEVIATION 0.54 • n=107 Participants
1.92 ml
STANDARD_DEVIATION 0.66 • n=206 Participants
Total Cholesterol
157.29 mg/dL
STANDARD_DEVIATION 47.10 • n=99 Participants
144.45 mg/dL
STANDARD_DEVIATION 28.85 • n=107 Participants
152.25 mg/dL
STANDARD_DEVIATION 41.08 • n=206 Participants
LDL
86.48 mg/dL
STANDARD_DEVIATION 40.52 • n=99 Participants
80.90 mg/dL
STANDARD_DEVIATION 26.77 • n=107 Participants
84.29 mg/dL
STANDARD_DEVIATION 35.57 • n=206 Participants
Triglycerides
142.23 mg/dL
STANDARD_DEVIATION 100.95 • n=99 Participants
109.90 mg/dL
STANDARD_DEVIATION 50.86 • n=107 Participants
129.55 mg/dL
STANDARD_DEVIATION 85.74 • n=206 Participants
Waist Circumference
42.66 inches
STANDARD_DEVIATION 5.21 • n=99 Participants
41.31 inches
STANDARD_DEVIATION 4.65 • n=107 Participants
42.13 inches
STANDARD_DEVIATION 4.99 • n=206 Participants
Weight
205.73 lbs
STANDARD_DEVIATION 39.22 • n=99 Participants
194.50 lbs
STANDARD_DEVIATION 36.62 • n=107 Participants
201.32 lbs
STANDARD_DEVIATION 38.25 • n=206 Participants

PRIMARY outcome

Timeframe: at 6 months

Population: Subjects analyzed were only those subjects with ST depression at baseline

Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.

Outcome measures

Outcome measures
Measure
Androgel
n=10 Participants
Androgel 5 grams
Placebo
n=11 Participants
Matching Placebo
Cardiac Stress Test: Time to ST Depression
at 1 month
439.1 seconds
Standard Deviation 205.2
279.5 seconds
Standard Deviation 130.0
Cardiac Stress Test: Time to ST Depression
at 3 months
364.0 seconds
Standard Deviation 141.4
292.6 seconds
Standard Deviation 63.5
Cardiac Stress Test: Time to ST Depression
at 6 months
433.0 seconds
Standard Deviation 123.2
342.2 seconds
Standard Deviation 62.7

PRIMARY outcome

Timeframe: At 1 month, 3 months, and 6 months

Population: Subjects analyzed were only those subjects with ST depression at baseline

Exercise capacity was measured using exercise time.

Outcome measures

Outcome measures
Measure
Androgel
n=10 Participants
Androgel 5 grams
Placebo
n=11 Participants
Matching Placebo
Cardiac Stress Testing: Exercise Capacity
at 6 months
614.0 seconds
Standard Deviation 115.4
470.0 seconds
Standard Deviation 143.8
Cardiac Stress Testing: Exercise Capacity
at 1 month
589.7 seconds
Standard Deviation 114.6
452.4 seconds
Standard Deviation 122.7
Cardiac Stress Testing: Exercise Capacity
at 3 months
607.6 seconds
Standard Deviation 152.0
472.1 seconds
Standard Deviation 98.6

SECONDARY outcome

Timeframe: up to 6 months

A cardiac disease-related quality-of-life measure. The SAQ is a self-report instrument with 19 items that, yields five subscale scores: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important. Data not collected.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Population: Subjects analyzed were only those subjects with ST depression at baseline

The Reactive Hyperemia Index measures the endothelial function and predicts future coronary events. In general RHI values below 2 are categorized as endothelial dysfunction and have a greater plaque burden, whereas higher RHI values are considered normal or improved endothelial function. PAT is the technique to non-invasively assess endothelial function. It comprises finger probes to evaluate digital volume changes.

Outcome measures

Outcome measures
Measure
Androgel
n=10 Participants
Androgel 5 grams
Placebo
n=11 Participants
Matching Placebo
Reactive Hyperemia Index
At baseline
1.96 mls
Standard Deviation 0.72
1.85 mls
Standard Deviation 0.54
Reactive Hyperemia Index
at 1 month
1.85 mls
Standard Deviation 0.49
1.81 mls
Standard Deviation 0.52
Reactive Hyperemia Index
at 3 months
1.70 mls
Standard Deviation 0.49
1.77 mls
Standard Deviation 0.37
Reactive Hyperemia Index
at 6 moths
1.83 mls
Standard Deviation 0.58
1.74 mls
Standard Deviation 0.53

SECONDARY outcome

Timeframe: 6 months

IPSS has 7 questions related to symptoms, each item scored 1-5. Total score can range from 0 to 35 (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 ("delighted" to "terrible".) Data not collected.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Population: Subjects analyzed were only those subjects with ST depression at baseline

The Metabolic Equivalent of Task (MET), or simply metabolic equivalent, is a physiological measure expressing the energy cost of physical activities and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference metabolic rate, set by convention to 3.5 ml O2·kg-1·min-1 or equivalently

Outcome measures

Outcome measures
Measure
Androgel
n=10 Participants
Androgel 5 grams
Placebo
n=11 Participants
Matching Placebo
Metabolic Equivalents of Task (METS)
at baseline
11.0 METS units
Standard Deviation 2.2
9.0 METS units
Standard Deviation 1.3
Metabolic Equivalents of Task (METS)
at 1 month
11.4 METS units
Standard Deviation 2.2
9.0 METS units
Standard Deviation 1.9
Metabolic Equivalents of Task (METS)
at 3 months
11.9 METS units
Standard Deviation 3.0
9.2 METS units
Standard Deviation 1.5
Metabolic Equivalents of Task (METS)
at 6 months
12.2 METS units
Standard Deviation 2.2
9.4 METS units
Standard Deviation 2.3

SECONDARY outcome

Timeframe: At baseline, 1 month, 3 months, and 6 months

The scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)

Outcome measures

Outcome measures
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
Aging Male Symptoms (AMS)
Baseline
36.5 units on a scale
Standard Deviation 11.4
35.8 units on a scale
Standard Deviation 10.2
Aging Male Symptoms (AMS)
At 1 month
32.9 units on a scale
Standard Deviation 10.1
29.8 units on a scale
Standard Deviation 11.6
Aging Male Symptoms (AMS)
At 3 months
36.5 units on a scale
Standard Deviation 11.4
35.9 units on a scale
Standard Deviation 10.2
Aging Male Symptoms (AMS)
At 6 months
31.2 units on a scale
Standard Deviation 8.5
31.4 units on a scale
Standard Deviation 9.8

SECONDARY outcome

Timeframe: At baseline, 1 month, 3 months, and 6 months

Questions 1-5 15 of the IIEF relates to erectile function scale 0 - 30 (severe erectile dysfunction to no erectile dysfunction).

Outcome measures

Outcome measures
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
International Index of Erectile Function (IIEF)
at baseline
12.4 units on a scale
Standard Deviation 8.7
12.2 units on a scale
Standard Deviation 9.4
International Index of Erectile Function (IIEF)
at 1 month
14.1 units on a scale
Standard Deviation 9.0
10.1 units on a scale
Standard Deviation 9.2
International Index of Erectile Function (IIEF)
at 3 months
15.7 units on a scale
Standard Deviation 9.6
14.2 units on a scale
Standard Deviation 10.8
International Index of Erectile Function (IIEF)
at 6 months
15.0 units on a scale
Standard Deviation 10.0
12.5 units on a scale
Standard Deviation 9.7

SECONDARY outcome

Timeframe: At baseline, 1 month, 3 months, and 6 months

Questions 9-10 of the IIEF relates to orgasmic function scale 0 - 10 (from no impairment to severe impairment)

Outcome measures

Outcome measures
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
IIEF-II Orgasmic Function
at baseline
4.8 units on a scale
Standard Deviation 3.3
4.4 units on a scale
Standard Deviation 3.6
IIEF-II Orgasmic Function
at 1 month
5.9 units on a scale
Standard Deviation 3.5
4.2 units on a scale
Standard Deviation 4.2
IIEF-II Orgasmic Function
at 3 months
5.7 units on a scale
Standard Deviation 3.7
5.8 units on a scale
Standard Deviation 4.2
IIEF-II Orgasmic Function
at 6 months
6.1 units on a scale
Standard Deviation 3.4
5.5 units on a scale
Standard Deviation 4.3

SECONDARY outcome

Timeframe: At baseline, 1 month, 3 months, and 6 months

Questions 11-12 of the IIEF relates to sexual desire scale 0-10 (from very low to very high)

Outcome measures

Outcome measures
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
IIEF -III: Sexual Desire
at 6 months
6.6 units on a scale
Standard Deviation 2.4
5.5 units on a scale
Standard Deviation 2.6
IIEF -III: Sexual Desire
at baseline
5.0 units on a scale
Standard Deviation 2.1
5.4 units on a scale
Standard Deviation 1.8
IIEF -III: Sexual Desire
at 1 month
5.6 units on a scale
Standard Deviation 2.7
4.8 units on a scale
Standard Deviation 2.4
IIEF -III: Sexual Desire
at 3 months
6.3 units on a scale
Standard Deviation 2.3
5.6 units on a scale
Standard Deviation 2.0

SECONDARY outcome

Timeframe: At baseline, 1 month, 3 months, and 6 months

Questions 6,7, 8 of the IIEF relates to intercourse satisfaction scale 0 - 15 (from very dissatisfied to very satisfied)

Outcome measures

Outcome measures
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
IIEF-IV: Intercourse Satisfaction
at baseline
5.5 units on a scale
Standard Deviation 4.0
5.0 units on a scale
Standard Deviation 4.6
IIEF-IV: Intercourse Satisfaction
at 1 month
6.2 units on a scale
Standard Deviation 4.6
3.6 units on a scale
Standard Deviation 4.4
IIEF-IV: Intercourse Satisfaction
at 3 months
6.8 units on a scale
Standard Deviation 4.9
6.0 units on a scale
Standard Deviation 5.1
IIEF-IV: Intercourse Satisfaction
at 6 months
6.9 units on a scale
Standard Deviation 5.1
5.2 units on a scale
Standard Deviation 5.1

SECONDARY outcome

Timeframe: At baseline, 1 month, 3 months, and 6 months

Questions 13,14 of the IIEF relates to specifically to overall satisfaction scale from 0 - 10 (very dissatisfied to very satisfied)

Outcome measures

Outcome measures
Measure
Androgel
n=31 Participants
Androgel 5 grams
Placebo
n=20 Participants
Matching Placebo
IIEF-V: Over-all Satisfaction
at 3 months
5.2 units on a scale
Standard Deviation 2.9
5.2 units on a scale
Standard Deviation 3.0
IIEF-V: Over-all Satisfaction
at 6 months
6.0 units on a scale
Standard Deviation 3.0
4.9 units on a scale
Standard Deviation 3.2
IIEF-V: Over-all Satisfaction
at baseline
4.8 units on a scale
Standard Deviation 2.5
4.3 units on a scale
Standard Deviation 2.4
IIEF-V: Over-all Satisfaction
at 1 month
4.9 units on a scale
Standard Deviation 2.9
3.8 units on a scale
Standard Deviation 2.7

Adverse Events

Androgel

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Mary Ann McLaughlin

Icahn School of Medicine at Mount Sinai

Phone: (212) 241-3340

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place